A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets…

Satoshi Inoue,1 Yoji Saito,2 Satoru Tsuneto,3 Etsuko Aruga,4 Azusa Ide,1 Yasuyuki Kakurai5

1Clinical Development Department, R&D Division, Daiichi Sankyo, Tokyo,2Department of Anesthesiology, Faculty of Medicine, Shimane University, Shimane, 3Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, 4Department of Palliative Medicine, School of Medicine, Teikyo University, Tokyo, 5Biostatistics and Data Management Department, R&D Division, Daiichi Sankyo, Tokyo, Japan

Background: In Japan, there (more…)

Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™…

TORONTO, July 26, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (more…)

How This Biotech Could Dethrone Oxycodone In Treating Pain – Investor’s Business Daily

image-top-caption”>image-container”>Nektar shares hit a high Tuesday on positive news for its pain-relieving drug. (Nektar Therapeutics)

Nektar Therapeutics (NKTR) stock popped to a three-month high Tuesday after the biotech said its chronic pain drug, NKTR-181, showed significantly less abuse potential compared with an oft-abused opioid.

On the stock market today, Nektar stock lifted 5.3%, near 21.80, after earlier rising as much as 5.9% to touch (more…)